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The cellular prion protein, PrP
C, is neuroprotective in a
number of settings and in particular prevents cerebellar
degeneration mediated by CNS-expressed Doppel or in-
ternally deleted PrP (‘DPrP’). This paradigm has facilitated
mapping of activity determinants in PrP
C and implicated a
cryptic PrP
C-like protein, ‘p’. Shadoo (Sho) is a hypothe-
tical GPI-anchored protein encoded by the Sprn gene,
exhibiting homology and domain organization similar to
the N-terminus of PrP. Here we demonstrate Sprn expres-
sion and Sho protein in the adult CNS. Sho expression
overlaps PrP
C, but is low in cerebellar granular neurons
(CGNs) containing PrP
C and high in PrP
C-deﬁcient den-
dritic processes. In Prnp
0/0 CGNs, Sho transgenes were
PrP
C-like in their ability to counteract neurotoxic effects of
either Doppel or DPrP. Additionally, prion-infected mice
exhibit a dramatic reduction in endogenous Sho protein.
Sho is a candidate for p, and since it engenders a PrP
C-like
neuroprotective activity, compromised neuroprotective ac-
tivity resulting from reduced levels may exacerbate da-
mage in prion infections. Sho may prove useful in
deciphering several unresolved facets of prion biology.
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Introduction
Prions are the causative agents of neurodegenerative dis-
eases, which include bovine spongiform encephalopathy
(BSE) in cattle, scrapie in sheep, chronic wasting disease in
mule deer and elk, and Creutzfeldt–Jakob Disease (CJD) in
humans. The infectious agent is believed to consist of im-
properly folded forms of a host-encoded protein, the cellular
prion protein (PrP
C). Conversion of PrP
C into the disease-
associated isoform, PrP
Sc, is thought to be the primary
pathogenic event, although the mechanisms by which PrP
Sc
causes disease are poorly understood. PrP
C is absolutely
required for disease progression, as PrP knockout (Prnp
0/0)
mice do not succumb to disease and do not propagate
infectivity following intracerebral challenge with infectious
prions (Bu ¨eler et al, 1992, 1993).
The mammalian prion protein family currently consists of
two proteins: PrP
C which is expressed at high levels in the
central nervous system (CNS), and Doppel (Dpl), a molecule
with a similar three-dimensional structure, whose postnatal
expression is normally conﬁned to the testis (Silverman et al,
2000; Mo et al, 2001). Whereas a role for Dpl in the proper
functioning of the male reproductive system has been con-
ﬁrmed in two lines of Dpl knockout mice (Behrens et al, 2002;
Paisley et al, 2004), the function of PrP
C, a well-conserved
neuronal glycoprotein, comprises a conundrum, in part
because phenotypic alterations in Prnp
0/0 mice have been
subtle or disputed. One emerging area of consensus concerns
a protective effect of PrP
C against neuronal insults. In parti-
cular, PrP
C is upregulated following ischemic brain damage,
in both humans and mice (McLennan et al, 2004; Weise et al,
2004). PrP
C deﬁciency in mice increases infarct size following
cerebral artery occlusion and increases caspase 3 activation
(Spudich et al, 2005), and PrP
C overexpression improves
neurological behavior and reduces infarct volume in a rat
stroke model (Shyu et al, 2005). Another widely observed
and perhaps related phenomenon involves the ability of PrP
C
to protect against a variety of proapoptotic stimuli (Kuwahara
et al, 1999; Bounhar et al, 2001; Chiarini et al, 2002; Cui et al,
2003; Sakudo et al, 2005; Lee et al, 2006; Novitskaya et al,
2006). Strong evidence for a neuroprotective activity for PrP
C
against apoptosis in vivo has come from studies of transgenic
(Tg) mice expressing internally deleted forms of PrP or wild-
type (wt)Dpl within the CNS. The presence of Dpl in the brain
of Prnp
0/0 mice leads to a neurodegenerative syndrome
characterized by a profound apoptotic loss of cerebellar
cells (Nishida et al, 1999; Moore et al, 2001; Rossi et al,
2001). A similar phenotype is observed when N-terminally
truncated versions of PrP
C (DPrP) are expressed in the brain
(Shmerling et al, 1998). Remarkably, both syndromes are
abrogated by the coexpression of wt PrP
C. Recently, it has
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4038been shown that a smaller deletion restricted to the well-
conserved central domain of PrP is sufﬁcient to elicit a highly
toxic phenotype in Prnp
0/0 mice (Baumann et al, 2007; Li
et al, 2007). The above studies have led to a model in which
Dpl and DPrP initiate aberrant signaling through a hypothe-
tical prion ligand termed LPrP, a process which is blocked by
PrP
C binding (Flechsig et al, 2004). Assuming that the inter-
action between PrP
C and LPrP represents an essential physio-
logical event, the authors also proposed the existence of a
PrP
C-like protein termed p, which binds to LPrPand is capable
of compensating for the absence of PrP
C in Prnp
0/0 mice. To
this date, no candidates for p (or LPrP) have been put forward.
However, an open reading frame was discovered which,
when translated, exhibits homology to the central hydropho-
bic domain in PrP
C. This gene, denoted Sprn (‘shadow of the
prion protein’), is present from zebraﬁsh to humans and is
predicted to encode a short protein, Shadoo (Sho) (Premzl
et al, 2003). Sprn is located on chromosome 7 in mice, away
from the Prn gene complex on chromosome 2.
Building on the genetic interaction between PrP
C and Dpl or
DPrP, we have established an assay for PrP
C activity in
primary cultures of cerebellar granule cells (Drisaldi et al,
2004, and references therein). Here, cerebellar granule neu-
rons (CGNs) cultured from Prnp
0/0 mice are transfected with
plasmids encoding Dpl or PrPalleles of interest and individual
apoptotic events scored. This assay recapitulates the pheno-
types produced by multiple PrP alleles in Tg mice, including
neurotoxicity of both Dpl and DPrP, and neuroprotective
activity of PrP
C against the toxicity elicited by either Dpl
or DPrP. In conjunction with biochemical and histological
analyses, we have used the CGN assay to explore the proper-
ties of Sho. We now demonstrate that Sho is a GPI-anchored
neuronal glycoprotein present in the CNS from early postnatal
life. Not only is Sho PrP
C-like in its ability to protect against
both Dpl and DPrP toxicity in the CGN assay, but it is also
strikingly reduced in prion infections.
Results
Sho protein expression in N2a cells and brain
Motivated by the absence of obvious phenotypic defects in
adult Prnp
0/0 mice, we considered proteins that might overlap
functionally with PrP
C. One criterion was evolutionary con-
servation. In this regard, bioinformatic analyses by Premzl
and co-workers have yielded an interesting candidate in the
shape of the Sprn open reading frame present in genomic
DNA of species from mammals to ﬁsh (Premzl et al, 2003,
2004; Miesbauer et al, 2006) and which, unlike the hypothe-
tical Prnt gene (Makrinou et al, 2002; Premzl et al, 2004), is
present in the mouse genome. The architecture of the pre-
dicted Sho protein loosely resembles the ﬂexibly disordered
PrP N-terminus (Figure 1). Analyses of Sprn expression by
RT–PCR (Premzl et al, 2003) and interrogation of expressed
sequence tag databases (UniGene) imply expression in em-
bryonic and adult neuronal tissue as well as the retina and
visual cortex, but have yet to document spliced mRNAs.
Consequently, we evaluated Sho as a putative third member
of the prion gene family.
To address expression at the protein level, we raised anti-
bodies against Sho. Two antisera (‘04SH-1’ and ‘06SH-3’) were
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Figure 1 Domain structure of Dpl, PrPD32–121, PrPand Sho. a-Helices (A, B and C) are boxed. A basic repeat region in Sho is stippled and the
hydrophobic domain in PrP and Sho is striped. Neuroprotective ‘determinants’, sequences required for PrP’s neuroprotective action and
mapped genetically, are shown in boxed numbers, and an expanded view shows the central hydrophobic regions of PrP and Sho aligned with
the T-COFFEE algorithm. PrP and Sho deletions used in this study are bracketed alongside the alignment. Two residues that correspond to the
N-termini of human PrP ‘C1’ fragment are underlined.‘Neurotoxic’ and ‘neuroprotective’ refer to assays in cerebellar granule cell cultures or Tg
mice (see main text).
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whereas a third (‘06rSH-1’) was against full-length recombi-
nant mouse Sho(25–122) expressed in Escherichia coli
(Figure 2A) and recognizes an N-terminal epitope contained
within residues 30–61 (Supplementary Figure S1). Assessed
by Western blot of tissue lysates, 06rSH-1 was virtually devoid
of cross-reactive species (Supplementary Figure S1). Cross-
reactive species of molecular weights incompatible with
authentic Sho were present in analyses with antisera
04SH-1 and with 06SH-3, but these had varying intensities
and/or different molecular weights for the two antisera.
Consequently, the following comments are restricted to sig-
nals detected by two or more varieties of a-Sho antibodies.
Similar to PrP
C, murine Sho is revealed as being expressed
at the cell surface, N-glycosylated and sensitive to the GPI
anchor cleaving enzyme phosphatidylinositol-speciﬁc phos-
pholipase C (PI-PLC) in transfected N2a neuroblastoma cells
(Figure 2C–E). Following PNGaseF treatment, full-length Sho
has a molecular weight of 9.1kDa as assessed by SDS–PAGE
(predicted 9.5kDa). In addition to the full-length protein, a
fraction of the protein in transfected N2a cells has a faster
electrophoretic mobility (Figure 2E). In PrP, a well-documented
physiological ‘C1’ cleavage occurs just before the hydrophobic
tract at residues His111 and Met112 (human PrP numbering
scheme, underlined; Figure 1) both in cultured cells and in the
adult brain (Pan et al, 1992; Chen et al, 1995; Vincent et al,
2000). Since cell lysates for these analyses were prepared in the
presence of protease inhibitors, it is possible that an analogous
endoproteolytic processing could ﬁgure in the biogenesis of
Sho. A detailed description of truncated forms of Sho will be
presented elsewhere (Coomaraswamy et al,i np r e p a r a t i o n ) .
Analysis of mouse tissue by Western blotting deﬁned a
predominant glycosylated protein species of similar molecu-
lar weight to transfected full-length Sho (approximately
18kDa), and one that is developmentally regulated, appear-
ing at embryonic day 16 and persisting in early postnatal life
and in the brains of adults (Figure 3A and B). PNGaseF-
sensitive bands of identical molecular weights were observed
with two independent Sho antibodies, conﬁrming the authen-
ticity of the bands and the presence of Sho in the mouse CNS.
Sho signal was emphasized in membrane-enriched prepara-
tions from adult mouse brains, corroborating its membrane
anchorage (Figure 3C). In Western blots performed with a-
Sho86–100 antisera, Sho signal increased following treatment
with PNGaseF, suggesting that N-glycosylation at Asn107
partially occludes antibody binding at the adjacent epitope
for the peptide-directed antiserum.
Overlapping and complementary PrP
C/Sho expression
In situ hybridization using antisense-strand riboprobes pre-
pared against the mouse Sprn open reading frame (but not
sense-strand controls) yielded signals in the adult mouse
CNS. Analyses of the hippocampus and cerebellum revealed
prominent signals in the cell bodies of pyramidal cells and
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Figure 2 Analysis of recombinant Sho in E. coli and expression of murine Sho in cultured cells. (A) Schematic representation of the Sho
protein. The location of the mapped epitopes for a-Sho peptide antisera (04SH-1 and 06SH-3) and a-recombinant Sho (06rSH-1) are shown.
(B) Circular dichroism spectrum of recombinant mouse Sho, rSho(25–122). The spectral trace is consistent with a random coil conﬁguration.
(C) Cell surface expression of wt Sho and a mutant Sho allele lacking the hydrophobic tract in non-permeabilized transfected N2a cells as
demonstrated by immunocytochemistry. Scale bar, 50 microns. (D) Diminution of Sho signal in the cell lysates of Sho-transfected N2a cells
following pretreatment with increasing concentrations of PI-PLC. (E) Western blot showing expression of a wt Sho transgene in N2a cells with
or without PNGaseF treatment. A lysate from cells transfected with empty vector is included to show antibody speciﬁcity.
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comparison, Prnp has a broader pattern of neuronal expres-
sion (Kretzschmar et al, 1986; Taraboulos et al, 1992).
Immunohistochemistry for Sho protein yielded prominent
signals in the same cell types deﬁned by in situ hybridization
(Figure 4D and L), that is, hippocampal neurons and cere-
bellar Purkinje cells. In the case of antisera 04SH-1, these
signals were absent when antibodies were preincubated in a
solution containing the Sho86–100 peptide immunogen
(Figure 4C and K). Besides deﬁning Sho as the ‘second’
cellular prion protein present in neurons of the adult CNS,
these data deﬁne intracellular transport phenomena, as im-
munohistochemical signals were present in cell processes in
addition to the cell bodies detected by antisense riboprobes
(i.e., predicted to contain Sho mRNA). In the case of Purkinje
cells, immunostaining was present not only in cell bodies but
also prominent in their processes, speciﬁcally in the dendritic
arborizations present within the molecular layer of the
cerebellum (Figures 4L and 5F–H, signals detected with all
three antisera). A related phenomenon was observed in
the hippocampus, notably in CA1 pyramidal neurons. Here,
Sho immunoreactivity was absent from axonal projections
(with all three a-Sho antibodies), present in cell bodies
(seen by all three a-Sho antibodies), and notable in the
apical dendritic processes located in the stratum radiatum
of the hippocampus (strong signals with 04SH-1 and 06SH-3,
and a less intense signal with 06rSH-1) (Figures 4D and
5A–C).
Since PrP has been reported to possess an unusual prop-
erty for a GPI-linked protein, the ability to undergo basolat-
eral (dendritic) sorting in polarized cells in distinction to the
more typical apical (axonal) sorting, parallel analyses were
undertaken for PrP
C and Sho. PrP
C was examined at basal
levels from the (endogenous) Prnp gene, or expressed from a
cosmid transgene of the hamster PrP gene including 25kb of
sequences 50 to the transcriptional start-site (Scott et al, 1989;
Prusiner et al, 1990). In the case of wt mouse PrP, analyses
were performed with 7A12 antibody (Li et al, 2000) using
Prnp
0/0 mice as negative controls (Figure 4E and M), whereas
non-Tg wt mice served as negative controls for the use of the
hamster PrP transgene-speciﬁc 3F4 antibody (Figure 4G and
O). Besides the anticipated differences in signal levels
between wt and Tg(SHaPrP)7 mice, the PrP
C-directed anti-
bodies yielded similar expression patterns, with widespread
staining throughout the brain. PrP
C was underrepresented in
the cell bodies of the pyramidal neurons of the hippocampus
but abundantly present in the stratum oriens containing the
axonal projections, and also in the radiatum, lacunosum
moleculare and molecular layers (Figure 4F and H). In the
cerebellum, mouse PrP
C was absent in wt Purkinje cells (as
described previously (Liu et al, 2001; Baumann et al, 2007))
and hamster PrP
C was represented in some but not all
Purkinje cells of Tg(SHaPrP)7 mice, and at a level lower
than that of the surrounding neuropil (Figure 4N and P). On
the other hand, PrP
C was present in the granule cell layer and
abundant in the molecular layer. Strikingly, the abundant
signal present in the radiatum layer was not totally uniform,
and—by virtue of a negative staining effect—revealed the
outlines of Purkinje cell dendritic arborizations in the cere-
bellum and the apical dendritic of CA1 neurons (Figure 5D–E,
and I–J): these are structures with marked immunostaining
with a-Sho86–100 (04SH-1 and 06SH-3) and a-rSho
(06-rSH1); Figure 5A–C and F–H). These data therefore
deﬁne a complementary ‘interlocking’ aspect to PrP
C/Sho
protein expression in the cerebellum and suggest a similar
effect in the hippocampus.
Although the most prominent Sho signals were obtained in
the hippocampus and cerebellum (Figure 4), signals for both
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Figure 3 Analysis of mouse Sho in tissue preparations. (A) Expression of Sho in whole mouse embryos assessed by Western blotting using a
12% Tris–glycine gel. Sho is expressed beginning at embryonic day 16. (B) Postnatal expression of Sho in neonatal and adult mouse brains with
or without PNGaseF treatment assessed by Western blotting using 14% Tris–glycine (a-rSho) or 4–12% NuPAGE (a-Sho(86–100) peptide and
a-PrP) gels. Full-length species before and after enzymatic treatment are bracketed. (C) Sho is present in a membrane-enriched fraction
prepared from mouse brains. Membrane preparations with or without PNGaseF treatment were analyzed on 4–12% NuPAGE gels by Western
blotting. Sho was detected using either a-Sho peptide polyclonal 04SH-1 (A–C) or a-recombinant Sho polyclonal 06rSH-1 (B), whereas PrP was
probed with single-chain antibodies D13 (A–B) or D18 (C).
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of the brain including the cerebral cortex, the thalamus, and
the medulla (Figure 5L–N; Supplementary Figure S2).
Coincidence with neuroﬁlament staining indicates that neu-
rons are the prominent site of Sho expression (Supplementary
Figure S2). PrP
C signal was abundant in these regions
(Figure 5, and data not shown), conﬁrming that Sho and
PrP
C expression proﬁles overlap in certain areas of the brain.
A further example of this phenomenon is apparent in the
adult retina (Premzl et al, 2003; Chishti et al, in preparation).
In overview, Sho expression within the adult mouse brain is
either less widespread than PrP
C, or basal Sho levels in
certain areas fall below the detection threshold of our current
procedures. Lastly, to assess whether there is a physiological
cross-regulation effect between PrP
C and Sho, we performed
a number of analyses on Prnp
0/0 mice (Supplementary Figure S4).
These failed to reveal a clear upregulation of Sho in response
to PrP
C deﬁciency.
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Figure 4 Localization of Sprn mRNA and Sho protein in the adult mouse brain. (A–H) The hippocampus, and (I–P) the cerebellum. wt C57/B6
mice are presented in all sections, with the exception of B6 congenic Prnp
0/0 (E, M) and Tg(SHaPrP)7 mice (H, P). Panels A, C, E, G, I, K, M and
O in the left-hand columns comprise negative controls (i.e., sense-strand riboprobes, peptide-directed antisera preincubated with a soluble
form of the antigenic peptide, Prnp
0/0 mice for PrP-directed antibodies) for analyses presented in the right-hand columns. In situ hybridization:
panels A, B, and I, J represent hybridizations with Sho sense-strand (A, I) or antisense (B, J) cRNA probe. Sections are not counterstained and
blue staining from NBT/BCIP substrate represents hybridization to Sprn mRNA. Immunohistochemistry: all other panels of mouse brains with
genotypes as noted above. Anti-Sho antibody 04SH-1 (a-Sho) antibody was used with (C, K) or without (D, L) preincubation with Sho(86–100)
peptide. Antibodies 7A12 and 3F4 were used for the detection of mouse PrP (E, F, M, N) and hamster PrP (G, H, O, P), respectively. Note the
Sho staining of CA1 apical dendritic processes (D, black bracket) and Purkinje cell layer (L, white arrow), and absence of Purkinje cell-body
staining with a-moPrP (N) and relative paucity of staining with a-HaPrP antibody (P, black arrow). Scale bar in panels A–H, and I–P, 100mm.
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Two N-terminal PrP modules, the charged region and the
copper-binding octarepeats, contribute to neuroprotective
activity in a neuronal assay (Drisaldi et al, 2004). However,
while others analyzed the same N-terminal modules, they
highlighted a trafﬁcking effect (Sunyach et al, 2003), so we
sought determinants beyond these potential delivery signals.
The C-terminus of PrP
C comprises a three-helix bundle (Riek
et al, 1996) similar to Dpl (Mo et al, 2001), and in the form of
alleles such as PrPD32–121 (Shmerling et al, 1998), exhibits
Dpl-like toxicity. We therefore focused on the ‘remaining’
area of PrP, residues 91–121 between the octarepeats and the
structured domain (Figure 1) containing the hydrophobic
domain (HD) with Sho homology. The deletion alleles were
tested for their ability to engender stable forms of PrP. As
anticipated from prior analyses of in-frame deletions
(Holscher et al, 1998; Shmerling et al, 1998; Hegde et al,
1999), these forms of PrP were synthesized at levels similar to
wt PrP, and also underwent similar maturation (Baumann
et al, 2007; Li et al, 2007) (Supplementary Figure S3).
Residues 100–105 are poorly conserved (Figure 1) and in
the cerebellar granule neuron (CGN) cellular assay (Drisaldi
et al, 2004), a PrPD100–105 allele exhibited protective activity
like wt PrP (Po0.001) when measured against Dpl.
Conversely, PrPD91–99 and PrPD106–112 alleles had de-
creased protective activity (neither is signiﬁcantly different
from Dpl alone; Figure 6B). PrPD106–121 transfected alone
exhibited partial neurotoxic activity approaching that of a
toxic PrPD32–121 control allele (Shmerling et al, 1998), but
different from that of wt PrP (Po0.01) (Figure 6A). These
data offer a parallel to assays in Tg mice. Here, deletions
invading the PrP central region from residues 91 to 121
produce proteins that are progressively toxic: no signiﬁcant
pathological abnormalities are noted in Tg mice expressing
PrP D32–80, D32–93, and D32–106, but mice expressing D32–
121 (or D32–134) exhibit profound loss of cerebellar cells
α-Shadoo
α-Shadoo mRNA
α-MoPrP  
α-HaPrP
I
O
M
K
J
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L
Figure 4 Continued.
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expressing PrPD94–134 or D105–125 (Baumann et al,2 0 0 7 ;
Li et al, 2007). From this we infer that a third determinant
of neuroprotection lies between PrP residues 91 and 99, and a
complex or modular activity determinant (‘determinant 4’)
lies between residues 106–121, whereby a D106–112 deletion
loses protective activity and a larger D106–121 deletion
exhibits partial neurotoxic activity. These data extend obser-
vations made in hippocampal neurons, where PrP residues
95–124 were implicated in neuroprotective action versus Dpl
(Lee et al, 2006).
Sho has PrP
C-like neuroprotective activity in a
functional assay
Sequence identity between Sho and PrP occurs in the
central hydrophobic region. Since this area is highly
conserved in PrP (Wopfner et al, 1999) and is predicted
to overlap or be immediately adjacent to determinants of
neuroprotective action (Figures 1 and 6B), we tested Sho in
a functional assay in Prnp
0/0 CGN cultures. Remarkably, a
wt mouse Sho cDNA was PrP
C-like in its ability to block
the proapoptotic action of cotransfected Dpl (Figure 6B)
(Po0.001 versus Dpl alone, no signiﬁcant difference
between wt PrP alone versus DplþSho). Since the putative
PrP
C-like activity called p was inferred from the action
of DPrP, rather than the action of Dpl (Shmerling et al,
1998), further experiments were carried out to assess the
effect of Sho upon the toxic action of a DPrP allele
(Figure 6C). In these cotransfections, wt Sho reduced
the toxic activity of singly transfected PrPD32–121 to a base-
line deﬁned by ‘empty vector’ (pBUD.GFP) controls
(Po0.001), and overlapping expression and colocalization
was apparent in transfected neurons (Figure 6E). Besides
adding to the similarities between Sho and p, these data
underscore the notion that DPrP and Dpl exert toxicity
through the same pathway.
Given the similarity between Sho and PrP in the HD, this
domain was a strong candidate for the ‘active site’ of Sho.
Consequently, we assessed the protective activity of Sho
F
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Figure 5 Reciprocal and overlapping expression of Sho and PrP
C in the CNS. (A–E) CA1 hippocampal neurons of adult mice probed as
indicated. The signal for Sho immunohistochemistry in apical dendrites of wt mice (A–C) has an equivalent in a ‘negative image’ (white
brackets) in the molecular layer of the neuropil imaged for either mouse PrP (D) or hamster PrP in Tg(SHaPrP)7 mice (E). Apical dendrites
were less intensely stained with the a-Sho 06rSH-1 antibody (C, black arrowhead) Analogous analyses are presented for Purkinje cells (F–J).
Somatodendritic localization of Sho in Purkinje cell bodies and dendritic arborizations (F–H) is contrasted by a reciprocal ‘negative image’ in
molecular layer of the neuropil imaged for either mouse PrP (I) or hamster PrP in Tg(SHaPrP)7 mice (J). Note the complete absence of MoPrP
staining in cell bodies (I, black arrowheads). Somatodendritic localization of calbindin in Purkinje cells of wt mice (K) is shown for
comparative purposes. (L–N) The cerebral cortex probed simultaneously with a-Sho (06rSH-1, green) and a-PrP (8H4, red) antibodies.
Overlapping PrP
C and Sho expression is observed in neurons of the cerebral cortex, including colocalization in cell bodies (N, white
arrowheads). Scale bar, 25mm (A–E), 10mm (F–K) or 20mm (L–N).
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ShoD62–77 allele was not protective against Dpl (not signiﬁ-
cant versus Dpl alone) (Figure 6B). wt and D62–77 Sho alleles
are expressed at similar levels in bulk-transfected cells, and
with immunoreactivity present upon the surface of trans-
fected N2a cells (Figure 2C; Supplementary Figure S1). In
contrast to a wt control allele, the ShoD62–77 allele also did
not exert signiﬁcant protection against a toxic PrPD32–121
allele (Po0.001 versus baseline of pBUD.GFP empty vector;
Figure 6C).
As an extrapolation from results presented above and from
prior analyses (Nishida et al, 1999; Moore et al, 2001; Rossi
et al, 2001), the ability of Dpl to cause cell death in Prnp
0/0
CGNs implies lack of a compensatory neuroprotective activity
(e.g., Sho) in these cells. To test this inference, and as an
additional control for immunohistochemical analyses pre-
sented in Figures 4 and 5, we assessed Sho expression in
the lysates of puriﬁed CGNs. Although Sho was readily
detected in brain lysate, the analysis failed to detect a
comparable signal in a normalized loading of CGN lysate
(Figure 6D).
Sho expression in prion-infected brains
To assess Sho in a disease setting, Western blots were
performed on brain homogenates from wt mice infected
with the RML isolate of mouse-adapted prions (Carlson
et al, 1986). Two independent cohorts produced in different
laboratories were used for this analysis. Assessed in the
clinical phase of disease, animals from both cohorts demon-
strated a striking reduction in Sho protein levels (Figure 7A
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Figure 6 Neuroprotective activity and Sho expression in CGN cells. Test for toxicity of PrP mutant alleles versus the performance of neurotoxic
wtDpl and PrPD32–121 controls in single transfections (A), results of cotransfections of PrP deletion mutants, wt Sho and pBUD.GFP empty
vector controls with wtDpl plasmid (B), and results of cotransfections to assess putative protective effects of Sho and internally deleted Sho
versus a toxic PrPD32–121 allele (C). Determinations (% cells7s.e.m undergoing apoptosis) reﬂect the results of two or more triplicate
transfections of independent batches of Prnp
0/0 CGNs scored by independent observers. Whereas PrPD100–105 and wt Sho had potent
neuroprotective activity (both Po0.001, n¼6, n¼11, respectively) not signiﬁcantly different from that of wt PrP, PrPD91–99 and PrPD106–112
exhibited a tendency for reduced neuroprotective activity against Dpl (neither cotransfection is signiﬁcantly different than Dpl single
transfections). ShoD62–77 cotransfections were not signiﬁcantly different from Dpl or PrPD32–121 single transfections. PrPD106–121
(n¼11) transfected alone was signiﬁcantly different from wt PrP (Po0.01; n¼15) and all other PrP alleles (Po0.001), with the exception
of the previously documented toxic PrPD32–121 allele (Shmerling et al, 1998): PrPD32–121 (n¼7) versus wt PrP, Po0.001. Cerebellar granule
cell assays for bioactivity, creation of plasmid constructs and veriﬁcation of protein expression were performed as described previously
(Drisaldi et al, 2004; Supplementary Figure 3) **Po0.01, ***Po0.001. (D) Western blot analysis using 06rSH-1 detects Sho in mouse brain
lysates but not in a normalized loading of lysate derived from mouse CGNs. ‘ns’¼non-speciﬁc bands detected by the antibody.
(E) Immunocytochemistry on non-permeabilized CGNs cotransfected with non-ﬂuorescent Sho and PrPD32–121 plasmids (3:1 ratio).
Sho was detected with 06rSH-1 and PrPD32–121 with 8H4. Both Sho and PrPD32–121 are expressed in a single cell and colocalization is
observed in the cell body. Scale bar, 15mm.
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two distinct Sho antibodies with independent epitopes.
Normalized against Thy-1, another GPI-anchored neuronal
protein, Sho signals of RML-inoculated brain extracts versus
brain extracts from healthy controls were reduced eight-fold
(Figure 7B). Avariety of other neuronal proteins were probed
as internal controls (Figure 7C). Although mild loss of signal
was apparent for some of these—perhaps a direct conse-
quence of neuronal damage and death—in no instance did
these reductions approach those seen for Sho. As a further
control we assessed Sho levels in a widely used animal model
of Alzheimer’s Disease, TgCRND8 mice expressing a mutant
b-amyloid precursor protein transgene (Chishti et al, 2001).
Using mice in clinical phase of the disease (marked by overt
amyloid deposits, normalized Ab levels equaling those of
sporadic Alzheimer’s disease, and profound cognitive impair-
ment), no difference was apparent between TgCRND8 and
non-Tg mice with regards to Sho levels (Figure 7D). Thus,
depletion of Sho is absent in non-infectious CNS amyloidosis.
Discussion
Our ﬁrst conclusion is that Sho is a bona ﬁde neuronal
glycoprotein and the third member of the mammalian prion
protein family. Beyond mere sequence homology, Sho de-
monstrates a number of biochemical and cell biological
properties also exhibited by PrP
C. These include addition
of a GPI anchor, N-glycosylation at one or two sites and a
cleavage event likely positioned N-terminal to the hydropho-
bic tract (Figures 1 and 2C–E; Supplementary Figure S1).
Furthermore, there are functional redundancies between PrP
C
and Sho measured in CGN cells. Although Sho and PrP
C have
dissimilar N-terminal regions that may tailor their activities in
different neuroanatomic sites, we infer that the center of both
PrP
C and Sho comprises a functionally conserved and ancient
activity domain contributing to neuroprotection. In PrP
C-
deﬁcient areas of the brain, Sho may be particularly impor-
tant in ﬁlling-in a PrP-like activity. Although the exact
relevance of PrP
C/Sho neuroprotection against exogenous
stimuli versus in vivo brain physiology remains to be deci-
phered, a role against neuronal insults such as ischemic
damage seems plausible. Indeed, increased PrP
C expression
following stroke has been observed in both humans and mice
(McLennan et al, 2004; Weise et al, 2004).
A second conclusion is that the study of Sho may help
decipher the molecular mechanisms underlying physiological
signaling from the prion protein family. Here, some initial
hints can be inferred from mutational analysis. As deletions
invade the central region of PrP
C, not only is protective
activity lost, but the mutant PrPs gain spontaneous proapop-
totic activity, as shown by loss of the granule cell layer in Tg
mice (Flechsig et al, 2004), and echoed here by the divergent
performance of PrPD106–112 and D106–121 alleles in the
CGN assay. It is possible that a gain of proapoptotic function
for PrP within CA1 neurons when it is sterically blocked and
dimerized by antibodies against residues 95–105 proceeds by
a related mechanism (Solforosi et al, 2004). In any event, the
PrP
C central region deﬁned by genetic mapping (analyzed by
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or clinically ill (average of 172 days post-inoculation) RML prion-inoculated mice (C3H/C57BL6 background). Sho protein levels are notably
reduced in prion-infected brains. Levels of the GPI-anchored protein Thy-1 are shown for comparison purposes. (B) Quantitation of Sho
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inoculated mice versus control mice injected with a brain homogenate from healthy mice (C57BL6 background, 154 days post inoculation).
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unstructured in NMR studies (Donne et al, 1997; Riek et al,
1997) and the homologous region in Sho is likely to be
natively unstructured as well (Figure 2B). This region may
serve as a site for protein–protein interactions, and in this
regard, our results parallel and extend a model for signaling
from PrP
C protein complexes. Besides PrP
C, this model
involves a hypothetical ligand, LPrP, and a conjectural PrP
C-
like protein denoted ‘p’ (Shmerling et al, 1998; Flechsig et al,
2004). Two docking sites are posited between LPrP and PrP
C,
and one docking site between Dpl or DPrP and LPrP. Based on
sequence similarity and domain structure (Figure 1), bio-
chemical properties (Figure 2), a low level expression of Sho
in the cerebellar granule cells (Figures 4L and 6D), and
similar effects of wt PrP or Sho versus Dpl or PrPD32–121
in CGN assays (Drisaldi et al, 2004) (Figure 6B), Sho can be
seen to resemble p. In this scheme, sequences within or
around the hydrophobic domain of Sho or PrP
C would
comprise a docking site for LPrP, a site associated with a
protective effect. In PrP
C, partial loss of this site may confer
spontaneous neurotoxic behavior, consistent with the en-
hanced toxicity observed in Tg mice expressing PrP with
HD deletions (Baumann et al, 2007; Li et al, 2007). A second
site lying within the a-helical domain present in PrP, DPrP
and Dpl is associated with a toxic effect (i.e., as per DPrP and
Dpl) unless the ﬁrst site is also present (as in wt PrP
C)
(Shmerling et al, 1998; Cui et al, 2003; Drisaldi et al, 2004).
Even though the original LPrP–PrP
C–p model may prove
incorrect in a cell biological sense (i.e., that signaling may
have more to do with protection from toxic stimuli rather
than regulation of endogenous trophic signals), it provides a
useful framework for deciphering molecular interactions.
Certainly the ability to now perform studies with PrP, DPrP,
Dpl and Sho and assess responses within a cellular assay
should aid the identiﬁcation of authentic PrP interactors.
A third conclusion is that Sho may open a window to
pathological signaling events in prion disease. Studies of
scrapie-infected rodents support the concept of neuroana-
tomic ‘target areas’ that give rise to the clinical features of
disease (Kimberlin and Walker, 1986). Thus far, the mechan-
isms by which disease associated forms of PrP (PrP
Sc or
‘PrP
D’) might cause dysfunction in these target areas have
proven elusive (Flechsig et al, 2000). For example, whereas a
requirement for PrP
C was inferred from grafting tissue from
mice overexpressing PrP
C into Prnp
0/0 mouse brains and
performing prion challenge of chimeric mice (Brandner
et al, 1996), a genetic reconstitution experiment employing
an astrocyte-speciﬁc hamster PrP transgene demonstrated an
opposite effect, namely neuronal damage in PrP
C-deﬁcient
neurons upon prion challenge (Jeffrey et al, 2004). The
concept of pathogenesis in trans, that is, independent of
PrP
C expression, is underlined by prior studies and by
experiments herein, which demonstrate that the dendrites
of CA1 neurons, an early ‘clinical target area’ in prion
infections, are largely devoid of PrP
C (Figure 5D and E).
Susceptibility of dendritic structures in this neuroanatomic
area has been demonstrated by several techniques in different
models of infectious prion disease (Hogan et al, 1987;
Johnston et al, 1997; Brown et al, 2001). We note that these
structures are strongly labeled by both Sho peptide directed
antisera in wt mice (Figure 5A and B), and are distorted and
attenuated in prion-infected mice (not shown), as already
described by others (Hogan et al, 1987; Johnston et al, 1997;
Brown et al, 2001).
Strikingly, Western blot analyses of brains from clinically
ill prion-infected mice revealed a dramatic reduction of Sho
protein (Figure 7). Because Sho has neuroprotective proper-
ties (Figure 6), it seems reasonable to consider whether a loss
of Sho may underlie some of the clinical or pathological
features of prion disease. In this regard, future studies utiliz-
ing Sprn
0/0 mice should prove informative. The mechanism
governing the loss of Sho protein during prion infections
remains to be determined. While a transcriptional effect
seems unlikely (not shown), protein structure may play a
role. Since Sho’s conserved region coincides with the epicen-
ter of PrP
C misfolding to disease-associated forms such as
PrP
Sc (Peretz et al, 1997, 2001; Beringue et al, 2004), con-
formational alterations in unstructured, cell-anchored Sho (or
in Sho shed into the parenchyma, like other GPI-anchored
proteins; Parkin et al, 2004) may occur upon interaction with
PrP
Sc. However, this does not explain how altered Sho
proteins, should they exist, might be more prone to degrada-
tion. Expanding the view to include the concept of aberrant
signaling may provide a more useful take on this problem.
Assuming that Sho exerts a neuroprotective function, pertur-
bations in this protective pathway could destabilize Sho or
lead to a loss of Sho-expressing cells and a commensurate
drop in protein level. According to this hypothesis, parench-
ymal PrP
Sc might interfere with the physiological protective
activity of Sho in trans by virtue of both its aberrant fold and
cell biological resemblance to Sho. While new experiments
will be required to probe the validity of these concepts and
the mechanisms controlling Sho expression, we suggest that
Sho is a potential modulator for the biological actions of
normal and abnormal PrP.
Materials and methods
Bioinformatics and statistics
Protein alignments were created using the T-COFFEE algorithm and
ESTsearches conducted using UniGene. Data sets for all transfected
constructs were assessed for normality (P40.10) by the Kolmogorov–
Smirnov test and analyzed by one-way ANOVA, Tukey pairwise
comparisons, with signiﬁcance set at Po0.05, using Prism software
(v4.0c, GraphPad Inc.).
Mouse lines, husbandry and inoculations
Zrch I Prnp
0/0 mice and littermates were maintained on a C57/B6
congenic background. Mice for inoculations, either C3H/B6 hybrids
(Toronto) or B6 inbred (McLaughlin Research Institute) were
inoculated intracerebrally with 30ml of 0.1% RML-infected brain
homogenate diluted in phosphate-buffered saline (PBS) containing
BSA (50mg/ml), penicillin (0.5U/ml) and streptomycin (0.5mg/
ml). Age-matched non-inoculated or mice inoculated with normal
brain comprised negative controls. Clinically ill mice were killed
and 10% brain homogenates in PBS were prepared. Proteinase K
digestions (50mg/ml) were performed at 371C for 1h. Sho levels
were calculated by densitometry (Scion Image) and comparison to a
standard curve created from serial dilutions of non-infected brain
homogenate. TgCRND8 mice (Chishti et al, 2001) on a C3H/C57BL6
outbred background were killed at clinical illness (B8 months) and
10% brain homogenates prepared in 0.32M sucrose containing
protease inhibitors.
Plasmid generation and recombinant protein
The Sho open reading frame was ampliﬁed from mouse genomic
DNA and inserted between the HindIII and XbaI sites of either
pcDNA3 or pBUD.CE4. GFP (Invitrogen). PrPand Sho mutants were
generated using methods previously described (Drisaldi et al, 2004),
with constructs veriﬁed by DNA sequencing (details available on
Shadoo and PrP
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ampliﬁed from pcDNA3.Sho and inserted between the NdeI and
BamHI sites of the pET-19b vector (Novagen) and expressed in
E. coli BL21(DE3)/RIL (Stratagene). Following induction and lysis,
ﬁltered lysate was subjected to Ni
2þ afﬁnity chromatography
(Qiagen), eluted with 250mM imidazole and dialyzed into 20mM
Tns–Hcl pH8.0, 100mM NaCl. The polyhistidine tag was removed
with enterokinase (Roche). Purity was assessed by SDS–PAGE and
concentration estimated using bovine serum albumin standards.
Far-UV circular dichroism spectra of recombinant Sho in PBS pH 7.0
and a protein concentration of 0.1mg/ml were collected at 221C
using a Jasco J-715 spectropolarimeter.
Sho antibody production
The peptide CRRTSGPGELGLEDDE (Sho residues 86–100 plus an N-
terminal cysteine) was conjugated to maleimide-activated KLH
(Pierce) and injected into New Zealand White rabbits. Alternatively,
recombinant Sho was conjugated to KLH using EDC (1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride) chemistry
(Pierce) and injected into rabbits. Antibodies were precipitated
from serum using ammonium sulfate and then afﬁnity puriﬁed
using the respective peptide (SulfoLink column) or polypeptide
(AminoLink Plus Coupling Gel column) immunogens. Epitope
positions are shown in Figure 2.
Cell culture and PI-PLC treatment
N2a cells, HEK293 and CGN cells were cultured, transfected and
lysed as described previously (Drisaldi et al, 2004), except that
staining for an activated caspase 3 neo-epitope (Cell Signaling
Technology) was used to quantify apoptotic events and conditioned
medium from adjacent wells replaced medium on transfected cells.
CGN assays represent two or more independent triplicate transfec-
tions into Prnp
0/0 cells, with observers being blind to the genotype
of transfected test plasmids. For PIPLC treatment, 24h post-
transfection, Sho-transfected N2a cells were washed three times
with PBS, and then treated with PI-PLC (Invitrogen) diluted in PBS
for 40min at 41C. Cells were then washed twice and lysed as above.
Immunocytochemistry and immunohistochemistry
N2a or HEK293 cells 24h post-transfection were washed with PBS,
ﬁxed with 4% paraformaldehyde, washed with PBS, blocked with
2% goat serum, then incubated with either Sho antibody (04SH-1,
6mg/ml) or PrP antibody (8H4, 1mg/ml), overnight at 41C.
Following PBS washes, cells were incubated with AlexaFluor488-
or AlexaFluor594-conjugated secondary antibodies (Invitrogen;
1:300) for 2h and then washed three times with PBS. For tissue
analysis, mice were saline-perfused. Brains were ﬁxed in Carnoy’s
ﬁxative (10% glacial acetic acid, 60% methanol, 30% chloroform)
bisected and processed. Six-micrometer sections were dried,
deparafﬁnized and taken to TBS (pH 7.2) for incubation with
primary antibody at 41C (anti-Sho 04SH-1 (1:100, this paper), anti-
Sho 06SH-3 (1:200, this paper), anti-Sho 06rSH-1 (1:50, this paper),
anti-PrP 3F4 (1:20000; Signet), anti-PrP 7A12 (1:10000; Li et al,
2000), and anti-calbindin D-28K (1:2000; Chemicon). Other anti-
bodies used include anti-Thy-1, R194 (a generous gift from Roger
Morris); anti-NSE, rabbit polyclonal from Polysciences Inc.; anti-
synaptophysin, SY38 from Chemicon; anti-actin, rabbit polyclonal
from Sigma (20–33); and anti-neuroﬁlament H, SMI-32 from
Sternberger Monoclonals Inc. For peptide blocking of antibody
reactivity, peptide was added in four-fold mass excess to Sho
antibody and incubated overnight at 41C before use. Sections were
rinsed in TBS and processed in DakoCytomation EnVision Labelled
Polymer, visualized with DAB (3,30-diaminobenzidine) and counter-
stained with Harris’ hematoxylin. Images were obtained with a
Leica DM6000B microscope using a Micropublisher 3.3RTV camera
(Q Imaging Inc.) and OpenLab4.0.4 software (Improvision). Images
in Figures 5L, M and 6E were de-convoluted using the iterative
restoration function in Volocity. For ﬂuorescent double labeling
experiments, the secondary antibodies used were AlexaFluor-488
(green) and AlexaFluor-594 (red)-conjugated antibodies (Invitro-
gen). For immunocytochemistry on CGNs (Figure 6E), cells were
ﬁxed 24h post-transfection in ice-cold methanol for 5min at  201C,
and then processed and stained.
In situ hybridization
pcDNA3.Sho plasmid was linearized with HindIII or BglII to
generate antisense and sense probes, respectively, using the DIG
RNA labeling kit (Roche). Sections (6mm) of formalin-ﬁxed brains
were cut using an RNase-free blade, mounted and dried overnight at
631C. Tissue processing and in situ hybridization was performed as
described by Peterson et al (2004). DIG-labeled RNA probes were
diluted 1/200–1/400 in hybridization buffer. Alkaline phosphate
substrate NBT/BCIP was added, color development performed for
16h in the dark and slides mounted without counterstaining.
Brain preparation and Western blotting
Mouse whole-brain homogenates were prepared in 0.32M sucrose
containing complete protease inhibitor cocktail (Invitrogen). For
preparation of crude membranes, homogenates were spun at 700g
for 10min at 41C, pellets washed with 1 volume of homogenization
buffer, spun again as above, supernatants were pooled then spun at
100000g for 1h at 41C and pellets resuspended in cold 50mM Tris–
HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 1% Triton X-100. After
spinning (100000g, 1h, 41C) the supernatant was stored at  801C.
Protein was separated on either NuPAGE 4–12% gels (Invitrogen)
using the MES buffer system, or by conventional SDS–PAGE using
14% polyacrylamide gels and transferred to either nitrocellulose
(PrP blots, 3% BSA block) or PVDF (Sho blots, 5% non-fat skim
milk block). Blots were incubated overnight with primary anti-
bodies (D13 or D18 at 0.5mg/ml for PrP (InPro Inc.), or 04SH-1 or
06rSH-1 Sho polyclonals at 1:500 or 1:2000, respectively, incubated
with HRP-conjugated secondary antibody and developed using
‘Western Lightning’ ECL (Perkin-Elmer). The embryo blot was
supplied from Zyagen (San Diego, CA), probed with 04SH-1 and
then stripped using 0.2M glycine pH 2.2, 1% Tween-20, 0.1% SDS,
followed by reprobing with D13 antibody
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
Acknowledgements
This work was supported by the Canadian Institutes of Health
Research (Grants MOP36377 and MSC46763) and a fellowship to
JCW from the Natural Sciences and Engineering Research Council
of Canada (PGSD2-319161-2005). We also acknowledge the travel
grants from the CIHR-Strategic Training in Health Research (STIHR)
initiative and the Canadian Network Centres of Excellence
(‘PrioNet’). DW is an Alberta Prion Research Institute Scholar. We
thank Nathalie Daude and Agnes Lau for bioinformatic analyses,
and Janice Robertson, Julie Forman-Kay and Rod Bremner for
discussions.
References
Baumann F, Tolnay M, Brabeck C, Pahnke J, Kloz U, Niemann HH,
Heikenwalder M, Rulicke T, Burkle A, Aguzzi A (2007) Lethal
recessive myelin toxicity of prion protein lacking its central
domain. EMBO J 26: 538–547
Behrens A, Genoud N, Naumann H, Ru ¨licke T, Janett F, Heppner FL,
Ledermann B, Aguzzi A (2002) Absence of the prion protein
homologue Doppel causes male sterility. EMBO J 21: 1–7
Beringue V, Vilette D, Mallinson G, Archer F, Kaisar M, Tayebi M,
Jackson GS, Clarke AR, Laude H, Collinge J, Hawke S (2004)
PrPSc binding antibodies are potent inhibitors of prion replication
in cell lines. J Biol Chem 279: 39671–39676
Bounhar Y, Zhang Y, Goodyer CG, LeBlanc A (2001) Prion protein
protects human neurons against Bax-mediated apoptosis. J Biol
Chem 276: 39145–39149
Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi
Y, Marino S, Weismann C, Aguzzi A (1996) Normal host prion
protein necessary for scrapie-induced neurotoxicity. Nature 379:
339–343
Shadoo and PrP
C
JC Watts et al
The EMBO Journal VOL 26 | NO 17 | 2007 &2007 European Molecular Biology Organization 4048Brown D, Belichenko P, Sales J, Jeffrey M, Fraser JR (2001) Early
loss of dendritic spines in murine scrapie revealed by confocal
analysis. Neuroreport 12: 179–183
Bu ¨eler H, Aguzzi A, Sailer A, Greiner R-A, Autenried P, Aguet M,
Weissmann C (1993) Mice devoid of PrP are resistant to scrapie.
Cell 73: 1339–1347
Bu ¨eler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ,
Prusiner SB, Aguet M, Weissmann C (1992) Normal development
and behaviour of mice lacking the neuronal cell-surface PrP
protein. Nature 356: 577–582
Carlson GA, Kingsbury DT, Goodman PA, Coleman S, Marshall ST,
DeArmod SJ, Westaway D, Prusiner SB (1986) Linkage of prion
protein and scrapie incubation time genes. Cell 46: 503–511
Chen SG, Teplow D, Parchi P, Gambetti P, Autilio-Gambetti L (1995)
Truncated forms of the human prion protein in normal brain and
in prion diseases. J Biol Chem 270: 19173–19180
Chiarini LB, Freitas AR, Zanata SM, Brentani RR, Martins VR,
Linden R (2002) Cellular prion protein transduces neuroprotec-
tive signals. EMBO J 21: 3317–3326
Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J,
Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G,
Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C,
Fraser PE, Carlson GA et al (2001) Early-onset amyloid deposition
and cognitive deﬁcits in transgenic mice expressing a double
mutant form of amyloid precursor protein 695. JB i o lC h e m276:
21562–21570
Cui T, Holme A, Sassoon J, Brown DR (2003) Analysis of doppel
protein toxicity. Mol Cell Neurosci 23: 144–155
Donne D, Viles JH, Groth D, Mehlhorn I, James TL, Cohen FE,
Prusiner SB, Wright PE, Dyson HJ (1997) Structure of the
recombinant full-length hamster prion protein PrP(29–231):
the N terminus is highly ﬂexible. Proc Natl Acad Sci USA 94:
13452–13457
Drisaldi B, Coomaraswamy J, Mastrangelo P, Strome B, Yang J,
Watts JC, Chishti MA, Marvi M, Windl O, Ahrens R, Major F, Sy
MS, Kretzschmar H, Fraser PE, Mount HT, Westaway D (2004)
Genetic mapping of activity determinants within cellular prion
proteins: N-terminal modules in PrP
C offset proapoptotic activity
of the doppel helix B/B0 region. J Biol Chem 279: 55443–55454
Flechsig E, Manson JC, Barron R, Aguzzi A, Weissmann C (2004)
Knockouts, knockins, transgenics and transplants in prion
research. In Prion Biology and Diseases, Prusiner SB (ed),
pp 373–434. Cold Spring Harbor, NY: Cold Spring Harbor Press
Flechsig E, Shmerling D, Hegyi I, Raeber AJ, Fischer M, Cozzio A,
von Mering C, Aguzzi A, Weissmann C (2000) Prion protein
devoid of the octapeptide repeat region restores susceptibility to
scrapie in PrP knockout mice. Neuron 27: 399–408
Hegde RS, Tremblay P, Groth D, DeArmond SJ, Prusiner SB,
Lingappa VR (1999) Transmissible and genetic prion diseases
share a common pathway of neurodegeneration. Nature 402:
822–826
Hogan RN, Baringer JR, Prusiner SB (1987) Scrapie infection
diminishes spines and increases varicosities of dendrites in
hamsters: a quantitative Golgi analysis. J Neuropathol Exp
Neurol 46: 461–473
Holscher C, Delius H, Burkle A (1998) Overexpression of noncon-
vertible PrP
C delta114–121 in scrapie-infected mouse neuroblas-
toma cells leads to trans-dominant inhibition of wild-type PrP(Sc)
accumulation. J Virol 72: 1153–1159
Jeffrey M, Goodsir CM, Race RE, Chesebro B (2004) Scrapie-speciﬁc
neuronal lesions are independent of neuronal PrP expression.
Ann Neurol 55: 781–792
Johnston AR, Black C, Fraser J, MacLeod N (1997) Scrapie infection
alters the membrane and synaptic properties of mouse hippo-
campal CA1 pyramidal neurones. J Physiol 500 (Part 1): 1–15
Kimberlin RH, Walker CA (1986) Pathogenesis of scrapie (strain
263K) in hamsters infected intracerebrally, intraperitoneally or
intraocularly. J Gen Virol 67: 255–263
Kretzschmar HA, Prusiner SB, Stowring LE, DeArmond SJ (1986)
Scrapie prion proteins are synthesized in neurons. Am J Pathol
122: 1–5
Kuwahara C, Takeuchi AM, Nishimura T, Haraguchi K, Kubosaki A,
Matsumoto Y, Saeki K, Yokoyama T, Itohara S, Onodera T (1999)
Prions prevent neuronal cell-line death. Nature 400: 225–226
Lee DC, Sakudo A, Kim CK, Nishimura T, Saeki K, Matsumoto Y,
Yokoyama T, Chen SG, Itohara S, Onodera T (2006) Fusion of
Doppel to octapeptide repeat and N-terminal half of hydrophobic
region of prion protein confers resistance to serum deprivation.
Microbiol Immunol 50: 203–209
Li A, Christensen HM, Stewart LR, Roth KA, Chiesa R, Harris DA
(2007) Neonatal lethality in transgenic mice expressing
prion protein with a deletion of residues 105–125. EMBO J 26:
548–558
Li R, Liu T, Wong BS, Pan T, Morillas M, Swietnicki W, O’Rourke K,
Gambetti P, Surewicz WK, Sy MS (2000) Identiﬁcation of an
epitope in the C terminus of normal prion protein whose expres-
sion is modulated by binding events in the N terminus. J Mol Biol
301: 567–573
Liu T, Zwingman T, Li R, Pan T, Wong BS, Petersen RB, Gambetti P,
Herrup K, Sy MS (2001) Differential expression of cellular prion
protein in mouse brain as detected with multiple anti-PrP mono-
clonal antibodies. Brain Res 896: 118–129
Makrinou E, Collinge J, Antoniou M (2002) Genomic characteriza-
tion of the human prion protein (PrP) gene locus. Mamm Genome
13: 696–703
McLennan NF, Brennan PM, McNeill A, Davies I, Fotheringham A,
Rennison KA, Ritchie D, Brannan F, Head MW, Ironside JW,
Williams A, Bell JE (2004) Prion protein accumulation and
neuroprotection in hypoxic brain damage. Am J Pathol 165:
227–235
Miesbauer M, Bamme T, Riemer C, Oidtmann B, Winklhofer KF,
Baier M, Tatzelt J (2006) Prion protein-related proteins from
zebraﬁsh are complex glycosylated and contain a glycosylpho-
sphatidylinositol anchor. Biochem Biophys Res Commun 341:
218–224
Mo H, Moore RC, Cohen FE, Westaway D, Prusiner SB, Wright PE,
Dyson HJ (2001) Two different neurodegenerative diseases
caused by proteins with similar structures. Proc Natl Acad Sci
USA 98: 2352–2357
Moore R, Mastrangelo P, Bouzamondo E, Heinrich C, Legname G,
Prusiner SB, Hood L, Westaway D, DeArmond S, Tremblay P
(2001) Doppel-induced cerebellar degeneration in transgenic
mice. Proc Natl Acad Sci USA 98: 15288–15293
Nishida N, Tremblay P, Sugimoto T, Shigematsu K, Shirabe S,
Petromilli C, Pilkuhn S, Nakaoke R, Atarashi R, Houtani T,
Torchia M, Sakaguchi S, DeArmond SJ, Prusiner SB, Katamine S
(1999) Degeneration of Purkinje cells and demyelination in the
spinal cord and peripheral nerves of mice lacking the prion
protein gene (Prnp) is rescued by introduction of a transgene
encoded for mouse Prnp. Lab Invest 79: 689–697
Novitskaya V, Bocharova OV, Bronstein I, Baskakov IV (2006)
Amyloid ﬁbrils of mammalian prion protein are highly toxic
to cultured cells and primary neurons. J Biol Chem 281:
13828–13836
Paisley D, Banks S, Selfridge J, McLennan NF, Ritchie AM, McEwan C,
Irvine DS, Saunders PT, Manson JC, Melton DW (2004)
Male infertility and DNA damage in Doppel knockout and
prion protein/Doppel double-knockout mice. Am J Pathol 164:
2279–2288
Pan KM, Stahl N, Prusiner SB (1992) Puriﬁcation and properties of
the cellular prion protein from Syrian hamster brain. Protein Sci 1:
1343–1352
Parkin ET, Watt NT, Turner AJ, Hooper NM (2004) Dual mechan-
isms for shedding of the cellular prion protein. J Biol Chem 279:
11170–11178
Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-
Ulms G, Mehlhorn IR, Legname G, Wormald MR, Rudd PM, Dwek
RA, Burton DR, Prusiner SB (2001) Antibodies inhibit prion
propagation and clear cell cultures of prion infectivity. Nature
412: 739–743
Peretz D, Williamson RA, Matsunaga Y, Serban H, Pinilla C,
Bastidas RB, Rozenshteyn R, James TL, Houghten RA, Cohen
FE, Prusiber SB, Burton DR (1997) A conformational transition at
the N terminus of the prion protein features in formation of the
scrapie isoform. J Mol Biol 273: 614–622
Peterson KE, Errett JS, Wei T, Dimcheff DE, Ransohoff R, Kuziel WA,
Evans L, Chesebro B (2004) MCP-1 and CCR2 contribute to non-
lymphocyte-mediated brain disease induced by Fr98 polytropic
retrovirus infection in mice: role for astrocytes in retroviral
neuropathogenesis. J Virol 78: 6449–6458
Premzl M, Gready JE, Jermiin LS, Simonic T, Marshall Graves JA
(2004) Evolution of vertebrate genes related to prion and Shadoo
proteins—clues from comparative genomic analysis. Mol Biol
Evol 21: 2210–2231
Shadoo and PrP
C
JC Watts et al
&2007 European Molecular Biology Organization The EMBO Journal VOL 26 | NO 17 | 2007 4049Premzl M, Sangiorgio L, Strumbo B, Marshall Graves JA, Simonic T,
Gready JE (2003) Shadoo, a new protein highly conserved from
ﬁsh to mammals and with similarity to prion protein. Gene 314:
89–102
Prusiner SB, Scott M, Foster D, Pan K-M, Groth D, Mirenda C,
Torchia M, Yang S-L, Serban D, Carlson GA, Hoppe PC,
Westaway D, DeArmond SJ (1990) Transgenetic studies implicate
interactions between homologous PrP isoforms in scrapie prion
replication. Cell 63: 673–686
Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R,
Wuthrich K (1996) NMR structure of the mouse prion protein
domain PrP (121–231). Nature 382: 180–183
Riek R, Hornemann S, Wider G, Glockshuber R, Wuthrich K (1997)
NMR characterization of the full-length recombinant murine
prion protein, mPrP(23–231). FEBS Lett 413: 282–288
Rossi D, Cozzio A, Flechsig E, Klein MA, Rulicke T, Aguzzi A,
Weissmann C (2001) Onset of ataxia and Purkinje cell loss in PrP
null mice inversely correlated with Dpl level in brain. EMBO J 20:
694–702
Sakudo A, Lee DC, Nakamura I, Taniuchi Y, Saeki K, Matsumoto Y,
Itohara S, Ikuta K, Onodera T (2005) Cell-autonomous
PrP–Doppel interaction regulates apoptosis in PrP gene-deﬁcient
neuronal cells. Biochem Biophys Res Commun 333: 448–454
Scott M, Foster D, Mirenda C, Serban D, Coufal F, Wa ¨lchli M,
Torchia M, Groth D, Carlson G, DeArmond SJ, Westaway D,
Prusiner SB (1989) Transgenic mice expressing hamster prion
protein produce species-speciﬁc scrapie infectivity and amyloid
plaques. Cell 59: 847–857
Shmerling D, Hegyi I, Fischer M, Blattler T, Brandner S, Go ¨tz J,
Rulicke T, Flechsig E, Cozzio A, von Meering C, Hangartner C,
Aguzzi A, Weissmann C (1998) Expression of amino-terminally
truncated PrP in the mouse leading to ataxia and speciﬁc cere-
bellar lesions. Cell 93: 203–214
Shyu WC, Lin SZ, Chiang MF, Ding DC, Li KW, Chen SF, Yang HI,
Li H (2005) Overexpression of PrP
C by adenovirus-mediated gene
targeting reduces ischemic injury in a stroke rat model. J Neurosci
25: 8967–8977
Silverman GL, Qin K, Moore RC, Yang Y, Mastrangelo P, Tremblay P,
Prusiner SB, Cohen FE, Westaway D (2000) Doppel is an
N-glycosylated, glycosylphosphatidylinositol-anchored protein:
expression in testis and ectopic production in the brains of
Prnp0/0 mice predisposed to Purkinje cell loss. J Biol Chem
275: 26834–26841
Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M,
Sugama S, DeGiorgio LA, Volpe BT, Wiseman E, Abalos G,
Masliah E, Gilden D, Oldstone MB, Conti B, Williamson RA
(2004) Crosslinking cellular prion protein triggers neuronal apop-
tosis in vivo. Science 303: 1514–1516
Spudich A, Frigg R, Kilic E, Kilic U, Oesch B, Raeber A, Bassetti CL,
Hermann DM (2005) Aggravation of ischemic brain injury by
prion protein deﬁciency: role of ERK-1/-2 and STAT-1. Neurobiol
Dis 20: 442–449
Sunyach C, Jen A, Deng J, Fitzgerald KT, Frobert Y, Grassi J,
McCaffrey MW, Morris R (2003) The mechanism of internaliza-
tion of glycosylphosphatidylinositol-anchored prion protein.
EMBO J 22: 3591–3601
Taraboulos A, Jendroska K, Serban D, Yang S-L, DeArmond SJ,
Prusiner SB (1992) Regional mapping of prion proteins in brains.
Proc Natl Acad Sci USA 89: 7620–7624
Vincent B, Paitel E, Frobert Y, Lehmann S, Grassi J, Checler F (2000)
Phorbol ester-regulated cleavage of normal prion protein in HEK293
human cells and murine neurons. JB i o lC h e m275: 35612–35616
Weise J, Crome O, Sandau R, Schulz-Schaeffer W, Bahr M, Zerr I
(2004) Upregulation of cellular prion protein (PrP
C) after focal
cerebral ischemia and inﬂuence of lesion severity. Neurosci Lett
372: 146–150
Wopfner F, Weidenhofer G, Schneider R, von Brunn A, Gilch S,
Schwarz TF, Werner T, Schatzl HM (1999) Analysis of 27 mam-
malian and 9 avian PrPs reveals high conservation of ﬂexible
regions of the prion protein. J Mol Biol 289: 1163–1178
The EMBO Journal is published by Nature
Publishing Group on behalf of European
Molecular Biology Organization. This article is licensed
under a Creative Commons Attribution License <http://
creativecommons.org/licenses/by/2.5/>
Shadoo and PrP
C
JC Watts et al
The EMBO Journal VOL 26 | NO 17 | 2007 &2007 European Molecular Biology Organization 4050